Researchers have found a metabolite in Burmese pythons that suppresses appetite in mice without some of GLP-1's side effects. And humans make it, too.
A new review fails to find much of any added weight loss benefit from intermittent fasting compared to typical diet advice.
The study, published last year, was found to contain unreliable and "implausible" data.
Researchers investigated why some people don’t respond as well to GLP-1 drugs and found that the reasons behind their overeating might play a role.
In a small trial, people lost more weight and fat while eating a diet rich in minimally processed foods than they did eating a diet high in ultra-processed foods.
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent mandate. Hims pushed back against the accusation.
Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose weight—without the nauseating symptoms now commonly seen with GLP-1 drugs.
Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.
MIT engineers have revealed a new gastric balloon design that can inflate on demand to make you feel full before meals.
A study of 14,000 WeightWatchers participants is the latest to suggest that Ozempic and similar obesity drugs could be adapted into treatments for substance use disorders.
A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.
Researchers have found "tremendous long-term outcomes" for teenagers who underwent surgery to treat their severe obesity a decade earlier.
New research estimates that expanded access to Ozempic and similar drugs could lead to 42,000 deaths prevented annually.
The rate of adult obesity has finally stopped climbing in recent years, new CDC data shows.
Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect our body? And what's left to learn?
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the average weight loss seen with semaglutide.
Scientists have developed a gel-based version of semaglutide that could reduce how often people need to take it.
GLP-1 drugs are effective weight loss tools, but exactly how they work is still mysterious.
A case report highlights the danger of mixing certain medications with the newest generation of weight-loss drugs.
Semaglutide doesn't work for everyone and can have side effects, but a study in mice may point to a solution.
